{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:37:56Z","timestamp":1773362276962,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally. Transarterial chemoembolization (TACE) is key for unresectable HCC, but patient outcomes vary, necessitating reliable prognostic markers. Although preoperative serum prealbumin (PAB) reflects nutrition and liver function and shows prognostic potential in single-center studies, high-level evidence is lacking. This meta-analysis aimed to systematically confirm the prognostic value of baseline serum PAB in HCC patients undergoing TACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Relevant publications up to February 3, 2026, were retrieved from PubMed, The Cochrane Library, Embase, Web of Science, CNKI, Wanfang, VIP, and CBM databases. Fixed-effect or random-effects models were used to calculate the pooled hazard ratio (HR) for overall survival (OS) and odds ratio (OR) for clinicopathological characteristics associated with serum PAB. Sensitivity and subgroup analyses investigated heterogeneity and assessed result stability. Publication bias analysis was conducted to evaluate the reliability of the meta-analysis findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight datasets from five studies were analyzed. Lower baseline PAB was significantly associated with poorer OS (pooled HR for high vs. low PAB = 0.64, 95% CI: 0.59\u20130.70, P&amp;lt;0.0001; random-effects model, I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). Higher PAB correlated with favorable features: earlier BCLC stage (OR = 2.23), better Child-Pugh class (OR = 5.36), absence of vascular invasion (OR = 0.44) or extrahepatic metastasis (OR = 0.22), smaller tumor size (OR = 0.51), single tumor (OR = 1.39), and lower AFP (OR = 0.56) (all P&amp;lt;0.05 except single tumor P = 0.020 and AFP P = 0.006). No significant association was found between prealbumin level and hepatitis B virus (HBV) infection status (P = 0.630). Subgroup and sensitivity analyses supported these findings, with no significant publication bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The analysis of 2,996 patients confirms that lower baseline serum PAB is significantly associated with poorer OS and unfavorable clinicopathological features in HCC patients receiving TACE. Further prospective and multi-center studies are needed to validate its clinical utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1782104","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:49:33Z","timestamp":1773319773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical utility of serum prealbumin levels as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: a meta-analysis of 2,996 patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Weiming","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Fuyang Campus of Zhejiang Provincial People\u2019s Hospital (The First People\u2019s Hospital of Fuyang)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Fuyang Campus of Zhejiang Provincial People\u2019s Hospital (The First People\u2019s Hospital of Fuyang)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunfeng","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Fuyang Campus of Zhejiang Provincial People\u2019s Hospital (The First People\u2019s Hospital of Fuyang)","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camm\u00e0","year":"2002","journal-title":"Radiology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4164130","DOI":"10.1155\/2017\/4164130","article-title":"Inflammatory markers as prognostic factors of survival in patients affected by hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"2017","author":"Rebonato","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15156","article-title":"Prognostic value of systemic immune-inflammation index\/albumin for transcatheter arterial chemoembolization treatment","volume":"9","author":"Tian","year":"2023","journal-title":"Heliyon"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/01.NURSE.0000511805.83334.df","article-title":"Using albumin and prealbumin to assess nutritional status","volume":"47","author":"Smith","year":"2017","journal-title":"Nursing"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0004563220931885","article-title":"Prealbumin: The clinical utility and analytical methodologies","volume":"59","author":"Ranasinghe","year":"2022","journal-title":"Ann Clin Biochem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.596691","article-title":"Dose-response between serum prealbumin and all-cause mortality after hepatectomy in patients with hepatocellular carcinoma","volume":"10","author":"Huo","year":"2020","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.10271","article-title":"Serum levels of prealbumin and albumin for preoperative risk stratification","volume":"34","author":"Loftus","year":"2019","journal-title":"Nutr Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.775425","article-title":"Preoperative serum prealbumin level and adverse prognosis in patients with hepatocellular carcinoma after hepatectomy: A meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-4992.2019.02.024","article-title":"The clinical value of serum prealbumin (PA) levels in the prognosis of patients undergoing TACE for liver cancer (in Chinese)","volume":"27","author":"Yu","year":"2019","journal-title":"Mod Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-794X.2022.06.013","article-title":"Predictive value of preoperative serum prealbumin for prognosis in patients with unresectable hepatocellular carcinoma undergoing TACE (in Chinese)","volume":"31","author":"Hou","year":"2022","journal-title":"J Interv Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18494","article-title":"Prognostic value of preoperative prealbumin levels in patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolisation","volume":"9","author":"Lei","year":"2023","journal-title":"Heliyon"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S433245","article-title":"Development and validation of a prognostic model for transarterial chemoembolization in unresectable hepatocellular carcinoma based on preoperative serum prealbumin","volume":"10","author":"Xu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-794X.2024.07.013","article-title":"Establishment and validation of a prognostic model incorporating serum prealbumin for unresectable hepatocellular carcinoma treated with TACE (in Chinese)","volume":"33","author":"Xu","year":"2024","journal-title":"J Interv Radiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jvir.2007.12.446","article-title":"Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials","volume":"19","author":"E","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.nu.14.070194.002431","article-title":"Transthyretin (prealbumin) in health and disease: nutritional implications","volume":"14","author":"Ingenbleek","year":"1994","journal-title":"Annu Rev Nutr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2019.1661501","article-title":"Prognostic value of prealbumin in liver cancer: A systematic review and meta-analysis","volume":"72","author":"Qiao","year":"2020","journal-title":"Nutr Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4359103","article-title":"C-reactive protein to prealbumin ratio (CPR): A novel inflammatory-nutritional prognostic factor for predicting cancer-specific survival (CSS) and overall survival (OS) in patients with resectable esophageal squamous cell carcinoma","volume":"2019","author":"Feng","year":"2019","journal-title":"J Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i44.6963","article-title":"Use of the alkaline phosphatase to prealbumin ratio as an independent predictive factor for the prognosis of gastric cancer","volume":"26","author":"Li","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6813176","article-title":"Prealbumin-to-globulin ratio can predict the chemotherapy outcomes and prognosis of patients with gastric cancer receiving first-line chemotherapy","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-020-1786-2","article-title":"Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis","volume":"18","author":"Sun","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.33160\/yam.2020.02.002","article-title":"Prognostic significance of C-reactive protein-to-prealbumin ratio in patients with esophageal cancer","volume":"63","author":"Matsunaga","year":"2020","journal-title":"Yonago Acta Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2012.650778","article-title":"Using a nutritional screening tool to evaluate the nutritional status of patients with colorectal cancer","volume":"64","author":"Tu","year":"2012","journal-title":"Nutr Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2014.11.007","article-title":"Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC)","volume":"34","author":"Sch\u00fctte","year":"2015","journal-title":"Clin Nutr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.1999.017","article-title":"Low levels of plasma proteins: malnutrition or inflammation","volume":"37","author":"Johnson","year":"1999","journal-title":"Clin Chem Lab Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1997.273.4.E720","article-title":"Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes","volume":"273","author":"Wigmore","year":"1997","journal-title":"Am J Physiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour","year":"2015","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10473-x","article-title":"Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis","volume":"17","author":"Gurbuz","year":"2023","journal-title":"Hepatol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/00075197-200111000-00002","article-title":"Inflammation-induced changes in the nutritional biomarkers serum retinol and carotenoids","volume":"4","author":"Schweigert","year":"2001","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.62347\/pjvg6340","article-title":"Clinical predictors for liver function impairment and post-embolization syndrome following transcatheter arterial chemoembolization in primary hepatic carcinoma patients: a retrospective study","volume":"15","author":"Zhao","year":"2025","journal-title":"Am J Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21461","article-title":"A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy","volume":"104","author":"Shimada","year":"2005","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-78","article-title":"Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma","volume":"13","author":"Oh","year":"2013","journal-title":"BMC Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.14035\/j.cnki.hljyy.2021.01.096","article-title":"Value of combined detection of serum prealbumin, cholinesterase, and total bile acid in the diagnosis of liver diseases (in Chinese)","volume":"34","author":"Huang","year":"2021","journal-title":"Heilongjiang Med J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04028-3","article-title":"Prognostic significance of systemic immune-inflammation index in hepatocellular carcinoma: a meta-analysis","volume":"28","author":"Li","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: Clinical Nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin Nutr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17435889.2025.2584581","article-title":"COX-2 gene silencing by laser-assisted oligonucleotides release from remote optical Nano-switches (LORONS) in hepatocellular carcinoma cells","volume":"20","author":"Awan","year":"2025","journal-title":"Nanomed (Lond)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:49:38Z","timestamp":1773319778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":46,"alternative-id":["10.3389\/fonc.2026.1782104"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1782104","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1782104"}}